Short Bowel Syndrome Clinical Trial
Official title:
The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome
Verified date | February 2017 |
Source | Jinling Hospital, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The efficacy of UDCA in treating the parenteral nutrition-associated cholestasis(PNAC) has been identified by some studies in children without short bowel syndrome(SBS).Most of the adults who suffering PNAC have SBS. it limits the potential function of UDCA because of the lack of SBS patients and malabsorption of UDCA.Therefore, we design this clinical trial in our center of SBS to approach the preventative and therapeutical effect of UDCA to PNAC in adults with short bowel syndrome.
Status | Completed |
Enrollment | 30 |
Est. completion date | September 2016 |
Est. primary completion date | April 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients with short bowel syndrome supported by total parenteral nutrition. - Patients have intestine more than 50cm. - Requirements of informed consent and assent of participant, parent or legal guardian as applicable - Consciousness and ability to cooperate. Exclusion Criteria: - Patients have obstruction of biliary tract, infection, autoimmune disease, cancer - Patients have intestine less than 50cm - A clinically significant laboratory abnormality or a history of significant cardiac, pulmonary, hepatic, or renal disease - Female with positive pregnancy - Allergy to ursodeoxycholic acid |
Country | Name | City | State |
---|---|---|---|
China | Jinling Hospital | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jinling Hospital, China | National Natural Science Foundation of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The biochemical indicator of patients' liver function during oral UDCA or placebo | detect the biochemical indicator of patients' liver function(Serum bilirubin, GGT Valley, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase) during oral UDCA or placebo | 2 months | |
Secondary | the changs of composition of serum bile acid after oral UDCA or placebo | we test the composition of serum bile acid at the beginning,2 months,4 months(the end) of the trial | 2 months | |
Secondary | The changs of the level of fibroblast growth factor 19(FGF19) in the serum | we test the level of FGF19 in the serum at the beginning,2 months,4months(the end) of the trail. | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05635747 -
A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
|
||
Completed |
NCT01891279 -
Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?
|
N/A | |
Completed |
NCT00930644 -
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
|
Phase 3 | |
Completed |
NCT01696656 -
Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency
|
N/A | |
Completed |
NCT00910104 -
Cholestasis Reversal: Efficacy of IV Fish Oil
|
Phase 2/Phase 3 | |
Completed |
NCT04981262 -
Improved Quality of Life in Children With Intestinal Failure
|
N/A | |
Completed |
NCT01930539 -
Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp
|
N/A | |
Recruiting |
NCT05023382 -
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
|
||
Recruiting |
NCT04733066 -
Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
|
||
Terminated |
NCT00742157 -
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
|
Phase 4 | |
Completed |
NCT04743960 -
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
|
N/A | |
Completed |
NCT03690206 -
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
|
Phase 3 | |
Terminated |
NCT02266849 -
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study
|
Phase 3 | |
Completed |
NCT01306838 -
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
|
Early Phase 1 | |
Completed |
NCT01380366 -
rHGH and Intestinal Permeability in Intestinal Failure
|
Phase 4 | |
Completed |
NCT00248573 -
Mechanisms of Adaptation in Human Short Bowel Syndrome
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03371862 -
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
|
Phase 2 | |
Completed |
NCT04474743 -
Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
|
||
Completed |
NCT00067860 -
Diet/Growth Factor Mechanisms of Gut Adaptation
|
Phase 2 | |
Terminated |
NCT04046328 -
Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome
|
Phase 2 |